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Abstract
Early or late pubertal onset affects up to 5% of adolescents and is
associated with adverse health and psychosocial outcomes. Self-
limited delayed puberty (DP) segregates predominantly in an auto-
somal dominant pattern, but the underlying genetic background is
unknown. Using exome and candidate gene sequencing, we have
identified rare mutations in IGSF10 in 6 unrelated families, which
resulted in intracellular retention with failure in the secretion of
mutant proteins. IGSF10 mRNA was strongly expressed in embry-
onic nasal mesenchyme, during gonadotropin-releasing hormone
(GnRH) neuronal migration to the hypothalamus. IGSF10 knock-
down caused a reduced migration of immature GnRH neurons
in vitro, and perturbed migration and extension of GnRH neurons
in a gnrh3:EGFP zebrafish model. Additionally, loss-of-function
mutations in IGSF10 were identified in hypothalamic amenorrhea
patients. Our evidence strongly suggests that mutations in IGSF10
cause DP in humans, and points to a common genetic basis for
conditions of functional hypogonadotropic hypogonadism (HH).
While dysregulation of GnRH neuronal migration is known to cause
permanent HH, this is the first time that this has been demon-
strated as a causal mechanism in DP.‡
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Introduction
Puberty is the critical developmental stage during which reproduc-
tive capacity is attained. The onset of puberty is driven by the reacti-
vation of the hypothalamic–pituitary–gonadal (HPG) axis after
relative quiescence during childhood, with an increase in the pulsa-
tile release of gonadotropin-releasing hormone (GnRH). While the
timing of pubertal onset varies within and between different
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populations, it is a highly heritable trait, suggesting strong genetic
determinants (Wehkalampi et al, 2008b). Previous epidemiological
studies estimate that 60–80% of the variation in pubertal onset is
under genetic regulation (Parent et al, 2003; Gajdos et al, 2009; Morris
et al, 2011). However, despite this strong heritability, little is known
about the genetic control of human puberty (Palmert & Dunkel, 2012).
Abnormal pubertal timing affects up to 5% of adolescents and is
associated with adverse health and psychosocial outcomes (He et al,
2010; Ritte et al, 2012; Widen et al, 2012; Day et al, 2015). Our lack
of understanding of the factors that trigger pubertal onset is a barrier
both to diagnosis and to the management of patients with pubertal
disorders, and also hampers attempts to comprehend the popula-
tion-wide trend toward an earlier age of pubertal onset in the devel-
oped world (DiVall & Radovick, 2008; Mouritsen et al, 2010).
Attempts to identify key genetic regulators of the timing of
puberty have ranged from genome-wide association studies of age
at menarche (Ong et al, 2009; Elks et al, 2010) to next-generation
sequencing approaches. Together, these studies suggest that puber-
tal timing in the general population may be controlled by hundreds
of genetic regulators, while loss-of-function mutations in one gene
can produce the phenotypic features of complete GnRH deficiency.
In patients with hypogonadotropic hypogonadism (HH), up to 30
separate genes resulting in severely delayed or absent puberty have
been identified (Bianco & Kaiser, 2009; Gajdos et al, 2009). These
genes control GnRH neuronal migration and differentiation, GnRH
secretion, or its downstream pathways (Karges & de Roux, 2005;
Beate et al, 2012). Evidence for digenic inheritance of HH, with
synergistic effects of two gene defects together producing a more
severe phenotype, has also been established (Pitteloud et al, 2007).
At the extreme end of the normal range of pubertal onset, self-
limited delayed puberty (DP) is a common condition (Sedlmeyer,
2002a). Self-limited DP is defined as the absence of testicular
enlargement in boys or breast development in girls at an age that is
2–2.5 standard deviations (SD) later than the population mean
(Palmert & Dunkel, 2012). DP segregates within families, with the
majority of families displaying an autosomal dominant pattern of
inheritance (Sedlmeyer, 2002b; Wehkalampi et al, 2008b). Recently,
variants in HH genes have been identified in some cases of self-
limited DP (Zhu et al, 2015). However, in the majority of patients
with DP, the neuroendocrine pathophysiology and its genetic regula-
tion remain unclear. Our large, well-phenotyped cohort with self-
limited DP from the relatively homogenous Finnish population
provides invaluable familial data with which to investigate this
question (Kristiansson et al, 2008; Wehkalampi et al, 2008b). We
hypothesized that such families will be enriched for low-frequency,
high- or moderate-effect alleles that are amenable to discovery
through exome sequencing.
Results
Rare, potentially pathogenic variants in the IGSF10 gene found in
10 families with DP
Initial whole exome sequencing performed in the 18 most extensive
families from our cohort (111 individuals: a total of 76 individuals
with DP, male = 53 and female = 23; and 35 controls, male = 13
and female = 22) identified 2,474,145 variants after quality control
(Fig 1). Following filtering through our in-house pipeline to identify
rare, predicted deleterious mutations, segregating with trait in an
autosomal dominant inheritance pattern in multiple families and
with potential biological relevance, 28 top candidate genes were
identified. These 28 genes were then put forward for targeted rese-
quencing in a further 42 families from the same cohort (178 individ-
uals with DP and 110 controls, Fig 1), and the filtered results were
analyzed by applying statistical thresholds for enrichment of rare,
pathogenic variants in our cohort via rare variant burden testing
with multiple comparison adjustment (Benjamini et al, 2001).
The candidate gene, immunoglobulin superfamily member 10,
IGSF10 (ENSG00000152580, gene identification number 285313),
was identified after rare variant burden testing (adjusted
P-value = 0.020) and screening of a further 100 controls from our
cohort (Fig 1). Four genes had initially passed the P < 0.025 thresh-
old after rare variant burden testing, and potentially pathogenic
variants in these genes were further analyzed to determine their
presence in controls from our cohort and for segregation with trait
(Appendix Table S1 and Fig 1). Following this analysis, IGSF10 was
found to be the most promising candidate, with four potentially
pathogenic variants in 10 probands from our cohort. The other 9 of
13 rare and potentially pathogenic variants that had been identified
in IGSF10 from targeted exome sequencing results were discarded in
our post-sequencing analysis, as they were present in multiple
controls from our cohort.
Four variants in IGSF10 identified in 31 individuals from 10
families (NM_178822.4: c.467G>T (rs138756085) p.Arg156Leu,
NM_178822.4: c.481G>A (rs114161831) p.Glu161Lys, NM_178822.4:
c.6791A>G p.Glu2264Gly and NM_178822.4: c.7840G>A
(rs112889898) p.Asp2614Asn) were found in ≤ 1 control subject
(Table 1, Figs 2A and EV1).
Although three of the four variants were present in public data-
bases, they were highly enriched in our cohort (Table 1). Analysis
of self-limited DP families is complicated by the fact that this pheno-
type represents the tail of a normally distributed trait within the
population, so it is anticipated that variants that govern the inheri-
tance of this condition will also be present in the general population
at a low level. Indeed, it is expected that up to 5% of the individuals
sequenced in population databases will have abnormal pubertal
timing, either early or delayed. Thus, the absence of these variants
in population databases cannot be used as an exclusion criterion,
and instead, a comparison of prevalence of such variants must be
made to identify those that are enriched in patients compared to the
ethnically matched general population.
All four IGSF10 variants are heterozygous missense variants
predicted to be deleterious, damaging, or possibly damaging by ≥ 3/5
prediction tools (Table 2). All variants affect amino acids that are
highly conserved among homologues, as revealed by PhyloP or
GERP score, and multiple sequence alignment (Table 2 and
Appendix Fig S1).
Families with IGSF10 variants display autosomal dominant
inheritance and classical self-limited DP
Two N-terminal variants in IGSF10 (p.Arg156Leu and p.Glu161Lys)
were identified in 20 individuals from six families (Figs 2A and
3A). Perfect segregation with the expected autosomal dominant
pattern of inheritance was seen in all but one individual
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Figure 1. Flowchart of exome sequencing filtering outcomes.
Whole exome sequencingwas initially performed onDNA extracted from the peripheral blood leukocytes of 111 individuals from the 18most extensive families fromour cohort
(76 with DP and 35 controls). The exome sequences were aligned to the UCSC hg19 reference genome. Picard tools and the genome analysis toolkit were used to mark PCR
duplicates, realign around indels, recalibrate quality scores, and call variants. Variants were analyzed further and filtered for potential causal variants using filters for quality
control, predicted functional annotation, minor allele frequency (MAF), segregation with trait, variants in multiple families, and biological relevance (see Materials and
Methods and Appendix Table S1 for further information on filtering criteria). Targeted exome sequencing using a Fluidigm array of 28 candidate genes identified post-filtering
was then performed in a further 42 families from the same cohort (288 individuals, 178with DP and 110 controls). Variants post-targeted resequencing were filtered using the
same criteria as thewhole exome sequencing data. Rare variant burden testingwas performed for all genes selected for targeted resequencing, in order to rank candidate genes
post-targeted resequencing. A multiple comparison adjustment was applied to the set of 28 P-values post hoc (Benjamini et al, 2001). Screening of 100 further cohort controls
was via conventional Sanger sequencing. Functional annotation of the variants as described elsewhere in Materials and Methods. DP, delayed puberty. *data unpublished.
Table 1. Minor allele frequency of IGSF10 variants in study population and control cohorts.
Nucleotide
change
Amino acid
change Exon
MAF from DP
patients
(%) (n = 215)
MAF from
controls
(%) (n = 210)
MAF (%)
Finnish/European/All
c.467G>T p.Arg156Leu 3 2.8 0 0/0.5/0.4
c.481G>A p.Glu161Lys 3 5.6 0.5 2.0/0.7/1.0
c.6791A>G p.Glu2264Gly 6 0.5 0 not seen
c.7840G>A p.Asp2614Asn 6 3.3 0 0/0.8/0.8
Minor allele frequency (MAF) data for the Finnish population were retrieved from The Sequencing Initiative Suomi (The SISu project) (http://www.sisuproject.fi/,
release 3.0, accessed September 2015). European and other MAF data were retrieved from the ExAC Browser (Exome Aggregation Consortium (ExAC), Cambridge,
MA: http://exac.broadinstitute.org, accessed September 2015).
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(family3.III.3), who was found to have DP without carrying the
variant. Of note given the known association between BMI and
pubertal timing, this individual was very lean (weight 13% below
median weight for height) at 13 years (Kaplowitz, 2008). The two
C-terminal variants (p.Glu2264Gly and p.Asp2614Asn), identified
in 11 individuals from four families, in contrast demonstrated
incomplete penetrance in family 7 and a possible de novo mutation
in family 10 (Fig EV1).
The affected individuals from these 10 families have classical
clinical and biochemical features of “simple” DP, with delayed onset
of Tanner stage 2 and delayed peak height velocity (Table 3). All
probands had low gonadotropins with low or undetectable sex
A B
Figure 2. Pedigrees of the families with N-terminal IGSF10 mutations with typical growth charts.
A Squares indicate male family members, and circles female family members. Black symbols represent clinically affected, gray symbols represent unknown phenotype,
and clear symbols represent unaffected individuals. The arrow with “P” indicates the proband in each family and “us” indicates unsequenced due to the lack of DNA
from that individual. The mutation in each family is given next to the family number; a horizontal black line above an individual’s symbol indicates that they are
heterozygous for that mutation as identified by either whole exome sequencing (family 3 and 4) or Fluidigm array (family 1, 2, 5, and 6), and verified by Sanger
sequencing.
B Growth charts of 2 probands each showing typical growth patterns of self-limited DP, without compromised linear growth before puberty. Solid horizontal black lines
connect green dots representing bone age to red dots at the equivalent chronological age.
Table 2. Prediction of IGSF10 variants according to web-based prediction software programs and conservation across species.
AA Change
dbSNP137
ID
PhyloP
(Pollard
et al, 2010)
Pred
SIFT
(Kumar
et al, 2009)
Pred
PolyPhen-2
(Adzhubei
et al, 2010)
Pred
LRT
(Chun &
Fay, 2009)
Pred
MutationTaster
(Schwarz
et al, 2014)
Pred
FATHMM
(Shihab
et al, 2013)
Pred
GERP
(Cooper
et al, 2005)
++
p.R156L rs138756085 C D D D N D 5.18
p.E161K rs114161831 C D D D D T 4.94
p.E2264G n/a C D P N D T 3.71
p.D2614N rs112889898 C D D D D T 5.24
C, conserved; D, deleterious, disease causing or damaging; P, possibly damaging; N, neutral; T, tolerated.
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AB C
Figure 3. IGSF10 protein structure and position of N-terminal mutations.
A IGSF10 domains and N-terminal mutations identified in the study. Region I contains leucine-rich repeats (LRR) 1-7 flanked by a LRR N-terminal (LRR Nt) and
C-terminal (LRR Ct) cap. Region II is structurally disordered. Region III contains two Ig-like domains (Ig). Region IV is structurally disordered. Region V contains
10 Ig-like domains (Ig).
B Protein tertiary structure as predicted by in silico analysis.
C Biological consequences of the 2 identified N-terminal mutations. Both WT and mutant N-terminal protein fragments (p.Arg156Leu and p.Glu161Lys) were expressed
in HEK293 cells as demonstrated by Western blotting. The GFP-tagged protein products of both were not detected in the conditioned media of mammalian cells, as
compared to wild type (WT), and appear to be retained in the intracellular compartment (mean  SEM; n = 3). Ponceau red staining is shown to demonstrate
equal protein loading for conditioned media. UT, untransfected negative control; nd, not detected; two-tailed t-test, n = 3 for each group, *P = 0.01094 (WT vs.
p.Arg156Leu) and P = 0.04408 (WT vs. p.Glu161Lys). It has to date not been possible to test cytoplasmic retention for the two C-terminal mutations due to difficulty
expressing the full-length or C-terminal protein fragment in mammalian cells.
Source data are available online for this figure.
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steroids and delayed bone age at presentation. In addition, these 10
probands displayed a typical growth pattern of self-limited DP, with-
out compromised linear growth before puberty (Fig 2B). Although
mean height SDS was below target height, the majority of patients
fell within normal limits. At adult height, all but two probands
(3.III.2 and 6.II.1) fell within normal limits for distance to target
height (Table 4). Birth length, birth weight, timing of pubertal
onset, and adult height of those with IGSF10 mutations were similar
to those of other affected DP individuals without IGSF10 mutations
from our cohort (Appendix Table S2).
In silico analysis of IGSF10
IGSF10 is a gene with thus far unclear function, mutations in which
have not previously been associated with human disease. The
IGSF10 protein has not previously been modeled by crystallography,
so we therefore performed in silico analysis (Figs EV2–EV4 and
EV5C, and Appendix Fig S2). In silico analysis of the protein reveals
five defined regions (Fig 3A and B). Region I, in which the two
N-terminal variants identified are located, contains leucine-rich
repeats (LRR) 1–7 flanked by a LRR N-terminal (LRR Nt) and
C-terminal (LRR Ct) cap. Region II is structurally disordered.
Region III contains two immunoglobulin-like beta sandwich
(Ig-like) domains. Region IV is structurally disordered. Region V,
in which the two C-terminal variants are located, contains 10
further Ig-like domains (Fig EV5B and C). No clear evidence for
a predicted transmembrane domain was provided by the in silico
analysis. However, published data give evidence for a putative
cleavage site with secretion of the N-terminal portion (Segev
et al, 2004).
Table 3. Clinical and laboratory data of DP probands from each of the 10 families with potentially pathogenic mutations in IGSF10.
Case 1.II.1 2.II.1 3.III.2 4.III.1 5.II.1 6.II.1 7.III.5 8.III.2 9.II.4 10.II.1
Clinical data at 1st assessment:
Sex M M M M M M M F M M
Age (years) 14.76 15.5 15.5 16.01 15.69 13.66 16.14 12.18 13.55 14.94
Bone agea 12.5 12.5 13.5 13.5 13.0 12.5 13 10.0 – –
Tvol 2.0/2.0 2.0/2.0 4.0/4.0 2.0/2.0 2.0/2.0 2.0/2.0 2.0/2.0 2.0/2.0 2.0/2.0
Ph. G or B stage 1.1 1.1 1.2 2.1 1.1 1.1 1.1 1.1 1.1 1.1
BMI 19.1 18 19.4 24.9 17.9 22.8 18.6 14.5 14.5 15
LHb (IU/l)
(0.1–0.6)c
0.3 0.1 0.4 0.1 0.2 0.1 0.1 0.1 0.15 0.15
FSHb (IU/l)
(0.1–0.9)c
0.45 0.1 0.5 0.3 0.6 0.35 0.6 0.2 0.5 0.3
Testosterone
(nmol/l)
(0.1–1.0)c
0.3 0.22 0.4 0.55 0.3 0.22 0.2 – 0.4 0.4
estradiol
(pg/ml)
(< 8)c
– – – – – – < 5
Inhibin B
(pg/ml)
(55–255)c
– 144 121 98 112 – – 168 155
Age at:
G2 or B2 15.2 15.6 15.5 16.5 16.10 15.21 16.5 13.94 15.21 15.4
Takeoff 14.76 15.81 15.6 16.11 15.59 15.6 16.5 13.94 15.5 15.91
PHV 15.6 16.2 17 17.3 16.2 16.18 17.3 14.68 16.1 16.4
Induction of puberty
Yes No No Yes Yes Yes Yes No No No
Age at start 14.76 16.11 15.59 15.21 16.5
Duration (months) 3 6 9 9 6
Olfaction
Self-
reported
normal
Self-
reported
normal
Self-
reported
normal
Self-
reported
normal
Self-
reported
normal
Self-
reported
normal
Self-
reported
normal
Self-
reported
normal
Self-
reported
normal
Self-
reported
normal
Tvol, testicular volume in mls; Ph, pubic hair; G, genital; B, breast stage; IU, international units; G2, genital stage 2; B2, breast stage 2; PHV, peak height velocity.
aBone age estimated by the Greulich and Pyle method.
bBaseline values.
cNormal ranges for prepubertal boys given in parentheses. Induction of puberty where indicated was with intramuscular testosterone esters.
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IGSF10 N-terminal mutant proteins display pathogenic features
with failure of extracellular secretion
The two N-terminal variants identified (p.Arg156Leu and
p.Glu161Lys) are located in region I within LRR domains (Fig 2A).
Both WT and mutant N-terminal protein fragments (668 aa in
length) were expressed in HEK293 cells as demonstrated by Western
blotting. However, while the GFP-tagged WT protein was detected
in the conditioned media, neither mutant protein could be detected
in their respective conditioned media. Moreover, a significant
increase in mutant protein was detected in cell lysates, suggesting
intracellular retention of these two mutants (Fig 3C).
Tissue expression studies localized Igsf10 mRNA expression to
the spatial and temporal window of GnRH neuronal migration
The expression of Igsf10 mRNA in the nasal region of mouse
embryos was analyzed from embryonic day (E) 10.5 to E17.5.
During this developmental window, GnRH neurons emerge from the
nasal placode (around E11) and then migrate toward the basal fore-
brain and hypothalamus (E12.5–E17.5) (Cariboni et al, 2007). Igsf10
mRNA expression was undetectable in the nasal region or forebrain
at E10.5 (Fig 4A). At E12.5, Igsf10 was prominently expressed in the
nasal mesenchyme (NM) with a decreasing gradient of expression
from the area surrounding the vomeronasal organ (VNO) toward
the nasal forebrain junction (NFJ), and absent in the VNO and olfac-
tory epithelium (OE) (Fig 4B). At E12.5, GnRH neurons are exiting
the VNO and migrating into an Igsf10 strongly positive cell milieu in
the NM (Fig 4B and C). At E14.5, GnRH cells and peripherin-
positive olfactory axons are navigating among the Igsf10-positive
NM cells (Fig 4D, G and H). Cxcl12, one of a plethora of molecules
known to provide directional cues to GnRH neurons (Memi et al,
2013), is also expressed in the NM, although with an opposite gradi-
ent compared to Igsf10 (Fig 4I). At E17.5, GnRH neurons are mainly
located in the medial preoptic area (MPOA, Fig 4J). Igsf10 signal
was not detected in the hypothalamus at E17.5. Igsf10-positive cells
were negative for isolectin b4 (marker of vasculature) at all
developmental stages (Fig 4E, at E14.5). Incubation with the sense
probe resulted in no signal at all stages. A similar expression pattern
of IGSF10 was detected in the nasal area of human embryos at 11
post-conceptual weeks (pcw) (Fig 4K–O), with GnRH neurons
navigating among the IGSF10-positive NM cells.
Igsf10 knockdown in vitro leads to reduced migration of
immature GnRH neurons
To investigate the functional role of Igsf10 in the migration of GnRH
neurons, we utilized a model of immortalized but migrating mouse
GnRH cells (Radovick et al, 1991). These GN11 cells express
neuronal markers and retain many features of immature GnRH-
secreting neurons (Wetsel, 1995; Gore & Roberts, 1997), including a
strong chemomigratory response in vitro (Maggi et al, 2000; Giaco-
bini et al, 2002; Pimpinelli et al, 2003). We performed co-culture
experiments of GN11 aggregates placed on confluent NIH3T3 mono-
layers. NIH3T3 cells, derived from a mouse embryonic fibroblast
cell line, express high levels of endogenous Igsf10. The NIH3T3 cells
were treated with scrambled- or Igsf10-shRNAs, the latter leading to
highly reduced levels of Igsf10 expression (Fig 5A). Migration of
GN11 across Igsf10-shRNA-treated NIH3T3 cells was found to be
significantly reduced compared to that across scrambled shRNA-
treated NIH3T3 (two-tailed t-test, n = 3 for both Igsf10-shRNA and
scr-shRNA with at least eight micromass replicates in each group,
P = 0.02422) (Fig 5B and C, analysis in D).
Igsf10 knockdown in vivo results in perturbed migration and
failed neurite extension of GnRH3 neurons
A transgenic zebrafish line, Tg(gnrh3:EGFP), was used to visualize
GnRH3 neurons and their projections. RT–PCR analysis indicated
high and relatively equal expression of Igsf10 mRNA at all time-
points tested during embryogenesis, from 48 h post-fertilization
(hpf) onward (Fig 5E). Morpholino-modified antisense oligonu-
cleotides (MOs) were used to repress Igsf10 mRNA to assess the
effect of Igsf10 knockdown on the development of the GnRH3
Table 4. Growth data of probands with IGSF10 variants.
Case Sex
Amino acid
alteration
Height SDS at
the age of
4 years
Height SDS at
the age of
8/9 years
Target
height
delta
HSDS
Distance to
target height
at 4 years
Distance to
target height
at 8/9 years
Adult
height
SDS
1.II.1 M p.Arg156Leu 1.1 1.3 0.4 0.2 0.7 0.9 0.9
2.II.1 M p.Arg156Leu 0.2 0.4 0.7 0.2 0.5 0.3 0.1
3.III.2 M p.Glu161Lys 0.5 0.8 0.7 0.3 1.2 1.5 0.9
4.III.1 M p.Glu161Lys 0.4 0.7 0.4 0.3 0.8 1.1 0.0
5.II.1 M p.Glu161Lys 0.3 0.2 0.9 0.1 1.2 1.1 0.9
6.II.1 M p.Glu161Lys 0.2 0 1.7 0.2 1.9 1.7 0.0
7.III.5 M p.Asp2614Asn 1 1.5 0.4 0.5 0.6 1.1 0.2
8.III.2 F p.Asp2614Asn 1.9 2.2 1 0.3 0.9 1.2 1.9
9.II.4 M p.Asp2614Asn 0.7 1.6 0.2 0.9 0.5 1.4 0.4
10.II.1 M p.Glu2264Gly 1.8 2 0.6 0.2 1.2 1.4 1.8
Height is expressed in SD score (SDS) for national reference data for Finland at 4 years of age, at either 8 years for girls or 9 years for boys, and at adult height.
Normal limits: delta HSDS < 1.21, distance to target height at 4 years < 1.76, distance to target height at 8/9 years < 1.72, distance to target height at adult
height < 1.44 (Saari et al, 2015).
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system. Time-lapse analysis of MO-injected Tg(gnrh3:EGFP)
embryos is shown in Fig 5F. At 48 hpf, GnRH3 neurons are
normally seen as bilateral dots in the olfactory organ–olfactory bulb
boundary. Over the following days, their projections extend caud-
ally through the telencephalon to the hypothalamus. The strongest
effect of morpholino injections was observed at 48 h. At this
time-point, the percentage of embryos showing an abnormal
GnRH3-neuron phenotype was higher in Igsf10 splice-site-MO
(Sp-MO)-injected embryos compared to relative controls, either
injected with a mispair morpholino (control-MO) or uninjected
(mean  standard error of mean: Sp-MO 33%  3.6 vs. control-MO
11.7%  1.5 vs. uninjected 2.8  1.3; one-way ANOVA, n = 201/
160/156 for Sp-MO/Ctrl-MO/uninjected, P = 0.000009, Fig 5G). A
similar effect was observed with the embryos injected with
Igsf10 ATG-MO. Igsf10 knockdown affected both the guidance and
the axonal outgrowth of GnRH3 neurons, which were unable to
form compact clusters or extend projections to the hypothalamus.
Loss-of-function mutation in IGSF10 in two patients with
functional hypogonadotropic hypogonadism
To explore the possible role of mutations in IGSF10 in conditions of
GnRH deficiency, we carried out targeted exome sequencing of
IGSF10 in an adult cohort of 334 patients with HH due to Kallmann
syndrome, idiopathic HH, or functional hypogonadism (hypothala-
mic amenorrhea (HA) or HA equivalent). This investigation showed
that 10.2% of these patients carried a rare, predicted damaging vari-
ant in IGSF10 (Appendix Table S3). Three loss-of-function variants
(NM_178822: c.C352T: (rs142596318) p.R118*, NM_178822:
c.G4804T: (rs79363433) p.E1602*, and NM_178822:
c.7353_7354insATCA: (rs570110855) p.L2452 fs) were identified in
a total of five patients, and 13 missense variants were identified
in 29 patients from our HH cohort, all in the heterozygous state. In
particular, all three of the loss-of-function variants were enriched in
our HH cohort as compared to the ExAC database.
Two patients (out of 14 patients from this HH cohort with
functional hypogonadism) were identified as heterozygous for a
shared loss-of-function mutation in IGSF10 (NM_178822:
c.7353_7354insATCA: (rs570110855) p.L2452 fs). This variant is
predicted to be deleterious with a high degree of confidence, with
the expected loss of the last two Ig-like domains of the IGSF10
protein. It is a rare variant in the general population, with a minor
allele frequency in the ExAC database of 0.01%. Both patients carry-
ing the variant had adult-onset functional hypogonadism associated
with environmental stressors. Patient 1 aged 31 years had a history
of secondary amenorrhea induced by excessive exercise, and
presented with failure to achieve spontaneous pregnancy. Patient 2
presented with adult-onset hypogonadism secondary to excessive
weight loss and a subclinical eating disorder. Neither patient had a
family history of HH, and both had normal pituitary imaging
and normosmia. (A more detailed summary is given in
Appendix Table S4.)
Discussion
The genetic control of the timing of puberty remains a fascinating
and largely unsolved puzzle. The inheritance of DP is known to be
under strong genetic influence with clear autosomal dominant segre-
gation of the trait within families, and thus represents a useful basis
for the investigation of puberty genetics. However, the genes
responsible for DP have not been identified, other than in a small
number of relatives of patients with HH (Lin et al, 2006; Pitteloud
et al, 2006; Tornberg et al, 2011; Vaaralahti et al, 2011; Zhu et al,
2015). In this study, our findings indicate a role for IGSF10 in the
migration of GnRH neurons and highlight two pathogenic mutations
in IGSF10 as the causal factor for DP in six unrelated families. We
have identified an additional two rare variants for unknown signifi-
cance in four further families.
IGSF10, a gene of previously unclear function, is a member of the
immunoglobulin superfamily. Loss-of-function mutations in another
member of this superfamily, IGSF1, were recently identified in
patients with X-linked central hypothyroidism (Sun et al, 2012).
Notably, male patients with IGSF1 mutations have a late increase in
testosterone levels with a delayed pubertal growth spurt.
Our functional work specifies a likely role of IGSF10 in the early
migration of GnRH neurons. The development of the HPG axis is
exceptional in that GnRH neurosecretory neurons develop in meta-
zoan embryos outside of the central nervous system. Immature
GnRH precursor neurons are first detectable in the olfactory placode
in the nose from an early embryological stage (E11 in mice) and then
begin a complex migration through the forebrain into the hypothala-
mus and preoptic areas (Cariboni et al, 2007; Wray, 2010).
An intact GnRH neurosecretory network is necessary for the
correct temporal pacing of puberty, as demonstrated by animal
models and the absence of pubertal development in patients with
HH (Ojeda et al, 2006; Colledge et al, 2010; Palmert & Dunkel,
2012). Our tissue expression studies localized IGSF10 mRNA expres-
sion to a spatial and temporal window when GnRH neurons are
migrating through the nasal mesenchyme (E11.5–17.5 in mice) to
the border with the telencephalon. Further evidence for the role of
IGSF10 in the regulation of GnRH neuronal migration was gained
from our in vitro demonstration of reduced migration of immortal-
ized GnRH neurons into a cell milieu with strongly reduced Igsf10
Figure 4. Expression pattern of Igsf10 mRNA in mouse and human developing brain.
A–J Igsf10 expression was not observed at E10.5 (A, sagittal section), but readily detectable at E12.5, in the NM (B and C, frontal sections), and E14.5, along the
migratory path of GnRH neurons (D, frontal section). Igsf10-positive cells were negative for isolectin b4 (a marker of vasculature) at all developmental stages (E, at
E14.5). Incubation with the sense probe resulted in no signal at all stages (E14.5 shown in F). Peripherin-positive cells olfactory axons were extending within the
Igsf10-positive NM (G and H). Cxcl12 mRNA expression is shown in I (E14.5, frontal section). GnRH neurons are located in the MPOA by E17.5 (J, frontal section) in
an Igsf10-negative area.
K–P In human 11pcw brains, IGSF10 expression pattern was similar to that observed in mouse, with GnRH neurons interspersed in an IGSF10-positive NM (K–M, frontal
sections, see also schematic in P). IGSF10-positive cells were also detected in the olfactory bulb (OB) (O). Sense probe resulted in no specific signal (N).
Data information: GnRH neurons are shown by red arrowheads and isolectin b4 by green arrowheads. NS: nasal septum. Scale bar, 250 lm (A), 100 lm (B, E, H), 50 lm
(C, K–O), 200 lm (D, F, G, I, J).
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expression. These results were additionally validated by the use of a
transgenic zebrafish model, where the depletion of Igsf10 via
injected MOs in zebrafish embryos resulted in perturbed migration
and failed neurite extension of GnRH3 neurons toward the
hypothalamus.
We hypothesize that immature GnRH neurons may respond to
IGSF10 signaling at the earliest stages of their migration, on exiting
the VNO. Pathogenic IGSF10 mutations, such as those identified
here, will disrupt IGSF10 signaling, potentially resulting in reduced
numbers or mis-timed arrival of GnRH neurons at the hypothala-
mus, the latter leading to a functional defect in the formation of the
GnRH neuroendocrine network. With this impaired GnRH system,
there would follow an increased “threshold” for the onset of
puberty, with an ensuing delay in pubertal timing. This relationship
has also been demonstrated in adult Reeler mice, which have signifi-
cantly fewer GnRH neurons in the hypothalamus and display a
phenotype of delayed pubertal maturation (Cariboni et al, 2005).
GnRH neurons are known to have receptors for at least 20 neuro-
transmitters. Migratory GnRH neurons receive a plethora of guid-
ance and movement-inducing messages during this journey, which
are likely to be distinct depending on the stage of their migration
(Tobet & Schwarting, 2006). Signals may act directly or indirectly
through the extension of olfactory axons, as disruption of the nerve
tract “scaffolds” themselves can disrupt GnRH migration (Gao et al,
2000). Gradients of chemokines may be particularly important for
promoting the movement of GnRH neurons (Tobet & Schwarting,
2006). The pattern of Igsf10 expression in the nasal mesenchyme
shows a ventral to dorsal gradient between the VNO and olfactory
bulbs, similar to a known axon-guidance gene, Cxcl12. Cxcl12 and
its receptor Cxcr4 are necessary for the guidance of GnRH neurons
toward the forebrain in both mouse (Toba et al, 2008) and zebrafish
(Palevitch et al, 2010) models. In the absence of intact Cxcl12/Cxcr4
signaling, GnRH neurons fail to properly migrate out of the nasal
mesenchyme during embryonic development.
The discovery of the role of IGSF10 contributes an additional
component to the highly complex system of secreted molecules and
chemotactic gradients directing GnRH neuronal migration in the
nasal region (Wray, 2010). The specific receptor(s) for secreted
IGSF10 protein, on the GnRH neurons or elsewhere, remains to be
determined. IGSF10, like GnRH, is also expressed in lung and other
tissues, where its function is as yet unknown. A degree of redun-
dancy with or compensation by other chemokines, such as has been
postulated for the GnRH neuron migratory cue semaphorin-4D, as
well as the action of potential “protective factors”, is feasible (Wray,
2010).
Furthermore, mutations in IGSF10 may contribute to the pheno-
type of other forms of secondary hypogonadism. Mutations that
perturb GnRH neuronal migration, including in KAL1 and PROKR2,
are already known to cause both HH and HA (Caronia et al, 2011).
Moreover, the same authors found that 25% of patients with HA in
their study had DP. DP is commonly found in relatives of patients
with HH and Kallmann syndrome. These findings imply that disrup-
tion to the GnRH network may result in a spectrum of phenotypes
from DP through HA to complete GnRH deficiency. Specifically, this
clinical variability can result from mutations in genes such as KAL1,
PROKR2, and now IGSF10, which may lead to late arrival or reduced
numbers of GnRH neurons to the hypothalamus, thus compromising
the function of the GnRH network. Moreover, an increasing burden
of mutations may produce a more severe outcome, with perhaps
one mutation leading to DP or HA, while two or even more muta-
tions may be required to lead to a phenotype of HH or KS. Our
finding of loss-of-function mutations in IGSF10 in two out of 14 indi-
viduals sequenced with HA and HA equivalent adds weight to this
suggestion, although sequencing of IGSF10 in a larger cohort of HA
patients would help to confirm this assertion. However, although
rare, predicted pathogenic variants in IGSF10 were enriched in our
HH cohort as compared to the general population, the presence of
such variants in the public databases suggests that these variants
alone are not sufficient to cause complete idiopathic HH or KS, again
in keeping with the above hypothesis.
In conclusion, our findings strongly support the contention that
mutations in IGSF10 cause delayed puberty in humans, through
dysregulation of GnRH neuronal migration during embryonic devel-
opment. Moreover, such mutations may also underlie susceptibility
to the phenotype of hypothalamic amenorrhea. Overall, this repre-
sents a new causal mechanism for self-limited DP and reveals a
shared pathophysiology between DP and other forms of functional
hypogonadism.
Materials and Methods
Patients
Initial whole exome sequencing was performed in 18 probands with
self-limited DP and their affected and unaffected family members
Figure 5. Effect of Igsf10 knockdown on GnRH neuronal migration.
A Levels of Igsf10 expression in native NIH3T3 cells, and cells stably expressing a scrambled (sh-scr) or Igsf10 (sh-Igsf10) shRNA.
B, C Migration of GN11 cells from aggregates into NIH3T3 sh-scr (B) or sh-Igsf10 (C).
D Analysis of the migration index (see Materials and Methods).
E RT–PCR analysis in zebrafish of total embryos and larvae showing the expression of Igsf10 mRNA at different time-points. Expected band size: 905 bp.
F Representative time-lapse analysis of mispair control (control Sp-MO and control ATG-MO) and Igsf10 morpholinos (Igsf10 Sp-MO and Igsf10 ATG-MO)-injected Tg
(gnrh3:EGFP) embryos and larvae, at different time-points. Images show lateral view of live larvae head (48 and 72 hpf) and dorsal view (4 and 5 dpf) of live larvae
head; anterior is left. White arrowheads indicate normal GnRH3 neuron clusters in the olfactory area of control embryos. Brackets show the extension of the
projections toward the hypothalamus. White arrows indicate examples of abnormal GnRH3 neurons scattered in the olfactory area of morphants accompanied by
the lack of projections toward the hypothalamus, indicated with D (hpf, hours post-fertilization; dpf, days post-fertilization). Scale bar, 100 lm (panels at 48 and
72hpf in F), 150 lm (panels at 4 and 5 dpf in F).
G Effect of Igsf10 splice-site morpholino injection observed at 48 h. Quantification of the percentage of embryos showing an abnormal GnRH3-neuron phenotype
was significantly higher in Igsf10 splice-site-MO (Sp-MO)-injected embryos compared to relative controls.
Data information: (A, D) two-tailed t-test, n = 3 for each group *P = 0.02422, **P = 0.00101. (G) one-way ANOVA with Dunnett’s post hoc test, n = 201/160/156 for
Sp-MO/Ctrl-MO/uninjected ***P = 0.00020, ****P = 0.00001. (A, D, G) error bars represent mean  SEM.
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from our previously described cohort (Wehkalampi et al, 2008a). In
brief, patients referred with DP to specialist pediatric care in central
and southern Finland between 1982 and 2004 were identified. All
patients (n = 492) met the diagnostic criteria for self-limited DP,
defined as the onset of Tanner genital stage II (testicular volume
> 3 ml) >13.5 years in boys or Tanner breast stage II > 13.0 years in
girls (i.e., two SD later than average pubertal development) (Palmert
& Dunkel, 2012). Medical history, clinical examination, and routine
laboratory tests were reviewed to exclude those with chronic illness.
HH, if suspected, was excluded by spontaneous pubertal develop-
ment at the follow-up. In the 50% of patients from the cohort who
choose to have pubertal induction via the use of exogenous sex ster-
oids, all patients were followed up once off treatment until the point
of full pubertal development (Tanner stage G4+ or B4+) to ensure
that pubertal development did not arrest off treatment.
Families of the DP patients were invited to participate, with infor-
mation about medical history and pubertal timing obtained by struc-
tured interviews and from archived height measurement records.
The criteria for the diagnosis of DP in family members were one of
the following three: (i) age at takeoff, or (ii) peak height velocity
(phv) occurring 1.5 SD beyond the mean, that is, age at takeoff
exceeding 12.9 and 11.3 years, or age at phv exceeding 14.8 and
12.8 years in males and females, or (iii) age at attaining adult height
more than 18 or 16 years, in males and females, respectively
(Wehkalampi et al, 2008a). All family members were assigned a
clinical status of affected, unaffected, or unknown. Those with
unknown status were either too young to diagnose or had insuffi-
cient growth data available.
Written informed consent was obtained from all participants.
A hypogonadotropic hypogonadism (HH) cohort of patients with
idiopathic hypogonadotropic hypogonadism (IHH, n = 158), Kall-
mann syndrome (KS, n = 162), and hypothalamic amenorrhea (HA)
or HA equivalent (n = 14) were collected through three coordinating
European centers (Newcastle upon Tyne Hospital, Newcastle, UK;
Biceˆtre University Hospital, Paris, France; and Robert Debre´ Hospi-
tal, Paris, France). Patients with IHH all had absent or incomplete
puberty at 18 years of age, low or normal serum gonadotropin
levels, low serum estradiol or testosterone levels, otherwise normal
anterior pituitary function, and normal results on neuroimaging. KS
patients had absent or incomplete puberty at 18 years of age, low or
normal serum gonadotropin levels, low serum estradiol or testos-
terone levels, otherwise normal anterior pituitary function, and
anosmia diagnosed clinically and by radiological evidence of olfac-
tory bulb disruption. Patients with HA or HA equivalent had a
history of spontaneous pubertal development with secondary amen-
orrhea in women for 6 months or more, low or normal gonado-
tropin levels, low serum estradiol or testosterone levels, and one or
more predisposing factors. These factors included excessive exercise
(> 5 h per week), or other stress, loss of more than 15% of body
weight, and either evidence of a subclinical eating disorder, or
another cause of dietary restriction (eg. self-perceived “intolerance”
to certain foods). Patients with frank anorexia nervosa or
BMI < 17 kg/m2 were excluded.
DNA sequencing and bioinformatics
Whole exome sequencing was initially performed on DNA extracted
from the peripheral blood leukocytes of 111 individuals from the 18
most extensive families from our cohort (a total of 76 individuals
with DP: male = 53 and female = 23, and 35 controls, male n = 13
and female n = 22), with exome capture on a Nimblegen V2 plat-
form or Agilent V5 platform and sequencing on the Illumina Hiseq
2000. The exome sequences were aligned to the UCSC hg19 refer-
ence genome. Picard tools and the genome analysis toolkit were
used to mark PCR duplicates, realign around indels, recalibrate
quality scores, and call variants.
Variants were analyzed further and filtered for potential causal
variants using filters for quality control, predicted functional
annotation, minor allele frequency, segregation with trait, variants
in multiple families, and biological relevance (Fig 1). Quality
control included thresholds for call quality, read depth, and
upstream pipeline filtering. Predicted functional annotation
involved prioritizing nonsense, exonic missense, splice-site vari-
ants, structural or promoter changes, or variants deleterious to a
microRNA. Filtering by MAF entailed including those variants
with minor allele frequency (MAF) < 2.5% in the 1000 Genomes
database, the NHLBI exome variant server, Sequencing Initiative
Suomi (sisu.fimm.fi), and dbSNP databases. Segregation with trait
refers to variants present in ≥ n1 affected individuals (where
n = the number of affected individuals in a given pedigree) and
not present in more than one unaffected individual being
retained. Multiple family filtering involved retaining those variants
seen in more than one family from the cohort sequenced, or with
different variants in the same gene in more than one family.
Biological relevance filtering allowed prioritization of those
remaining variants under three criteria: (i) Variants in genes
known to be relevant to the phenotype of HH; (ii) variants in
genes in linkage disequilibrium (r2 no limit, D prime > 0.8) with
loci associated with genome-wide association studies of age at
menarche (Elks et al, 2010); and (iii) variants in genes with
potential biological significance, using the tools Ingenuity Variant
Analysis (QIAGEN Redwood City, www.qiagen.com/ingenuity),
Genego MetaCore (Thomson Reuters), Ensembl variant effect
predictor, and Annovar (Wang et al, 2010).
Targeted exome sequencing using a Fluidigm array for library
preparation followed by Illumina Miseq sequencing of 28 candidate
genes identified post-filtering was then performed on DNA extracted
from the peripheral blood leukocytes of a further 42 families from
the same cohort (288 individuals, 178 with DP and 110 controls,
Fig 1). Variants post-targeted resequencing were filtered using the
same criteria as the whole exome sequencing data: on the basis of
quality control, predicted functional annotation, minor allele
frequency, and segregation with trait.
Rare variant burden testing was performed for all 28 genes post-
targeted resequencing. Fisher’s exact test was used to compare the
prevalence of deleterious variants in our cohort with the Finnish
population, using the ExAC Browser (Exome Aggregation Consor-
tium (ExAC), Cambridge MA: http://exac.broadinstitute.org,
accessed September 2015). For each of the 28 genes, all variants
from the ExAC database with minor allele frequency < 2.5%,
predicted to be deleterious by both Polyphen-2 (Adzhubei et al,
2010) and SIFT (Kumar et al, 2009), were included in the analysis,
with each family in our cohort represented by the proband only. A
multiple comparison adjustment was applied to the set of 28
P-values post hoc using the Benjamini and Hochberg method
(Benjamini et al, 2001). Variants identified following filtering
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pipelines were confirmed by conventional Sanger sequencing and
screened in a further 100 controls from our cohort via Sanger
sequencing.
The HH cohort (n = 334) was screened via targeted exome
sequencing for mutations in IGSF10 using a Fluidigm array for
library preparation followed by Illumina Miseq sequencing, with the
same filtering pipeline used for the whole and previous targeted
exome sequencing data. Variants identified were confirmed by
conventional Sanger sequencing.
Growth pattern analysis
The pattern of prepubertal growth in the 10 probands was analyzed
using two parameters: (i) HSDS distance from target height (TH)
at the ages of 4 and 8 (girls) or 9 (boys) years (TH
formula = 0.791 × mean parental height SDS0.147 for girls and
0.886 × mean parental height SDS0.071 for boys) and (ii) change
in height SDS (ΔHSDS) between the ages of 4 and 8/9 years. Normal
values for the two parameters, based on data from > 70,000 healthy
Finnish children, have been previously published (Saari et al, 2015).
In silico analysis
The amino acid sequence for human IGSF10 was retrieved from
UNIPROT database (id Q6WRI0). Homology modeling was used to
determine the 3D structure using two high-performing protein struc-
ture prediction servers: Phyre2 (Kelley & Sternberg, 2009; Jefferys
et al, 2010) and I-Tasser (Roy et al, 2010). The signal peptide cleav-
age site was calculated using SignalP4.1 (Petersen et al, 2011). The
following interactions involved in protein stability were considered:
(i) salt bridges, defined as at least one pair of atoms on oppositely
charged groups within a 4.5 A˚ distance; (ii) hydrogen bonds
(H-bond), defined as a donor–acceptor distance ≤ 2.5 A˚ and an angle
at the acceptor ≥ 90°; and (iii) disulfide bridge (S-S bridge) defined
as the side chains of two cysteines at a 3.0 A˚ distance. Pairs of
cysteines at a greater distance were also considered as potentially
forming an S-S bridge when found to be reasonably close (Ca-Ca
distance < 10A˚). We used Ca distance to allow for errors in side-
chain placement and a relatively high threshold to accommodate
possible deviation of the backbone from native. The protein electro-
static potential was calculated using PBEQ program (Jo et al, 2008),
which computes the protein electrostatic potential by solving the
Poisson–Boltzmann equation. Protein structures were visualized
using the Pymol visualization program (http://www.pymol.org/).
Constructs and protein expression
An N-terminal fragment encoding the first 668 aa of IGSF10 gene
(RefSeq NM_178822.3) was cloned into a pcDNA-EGFP (Addgene
plasmid #13031), and p.Arg156Leu and p.Glu161Lys variants were
generated using PCR-mediated mutagenesis (Quickchange II, Agilent
Technologies) according to the manufacturer’s instructions and veri-
fied by sequencing.
HEK293 (sourced from ATCC) were transfected with wild-type or
mutant plasmids using polyethylenimine (Sigma) via a standard
protocol. Cells were checked for mycoplasma contamination
(MycoAlert Detection Kit, Lonza) on a monthly basis and were
contamination-free. Transfected cells were selected with G418
(1 mg/ml, Sigma). Once stable cell lines were established, the cells
were cultured for 24 h in 6-well plates to full confluency in 1 ml of
media. This process was repeated on three separate occasions with
cells from the same stable cell lines, to produce technical replicates.
Conditioned media from each well were removed for analysis before
cell lysis with RIPA buffer (Sigma) supplemented with protease inhi-
bitors (Complete Mini, Roche). Lysates and conditioned media were
cleared by centrifugation at 16,060 g at 4°C for 10 min. Equal
amounts of lysates and conditioned media were size-separated
(NuPage BisTris gels 4–12%) and transferred to nitrocellulose
membranes (Promega). Post-transfer, the blots were stained with
Ponceau red to assess equal loading, blocked with PBS containing
0.1% Tween-20 and 5% nonfat dry milk, and incubated in a 1:500
dilution of mouse monoclonal anti-GFP (Roche, 1DB-001-
0000570956) antibody or a 1:3000 dilution of mouse monoclonal
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Santa
Cruz Biotechnology, 1DB-001-0000183498) for 12 h at 4°C. After
washes, the membranes were incubated with goat anti-mouse
IRDye680 (1:10000 dilution; Licor). Immunoblots were scanned with,
and protein relative amounts were calculated by, the Odyssey Fc
Imaging System (Licor).
Nonradioactive in situ hybridization
(NR-ISH)/Immunohistochemistry
E10.5 to E17.5 mouse embryos were collected from timed crosses of
C57BL/6 mice. The morning of the vaginal plug was designated
0.5 days; 11 post-conceptual weeks (pcw) human brains were
obtained from the MRC-Wellcome Human Development Biology
Resources (HDBR—Institute of Genetics Medicine, Newcastle, UK).
Tissues were fixed in 4% paraformaldehyde (PFA) in PBS, cryopro-
tected in 30% sucrose, and frozen in OCT compound (VWR);
12-lm-thick serial sagittal and coronal sections were collected on
Superfrost Plus slides (VWR).
Mouse and human Igsf10 were PCR-amplified from brain cDNAs
using the following primers: mIgsf10 FOR: 50-GCAAGAAGGAAA-
GAATCCCC -30, REV: 50- GATTCGCCCATCCTCACTAA -30; hIGSF10
FOR: 50-TCAGGAGCTTGACACGATTG-30, REV: 50- CTGCGGTGTTT
CACTAAGCA-30. Amplified cDNAs were cloned into the dual
promoter vector pGEM-T easy (Promega) and linearized with the
appropriate restriction enzymes. Mouse Cxcl12 probe was from
Memi et al (2013). Probe preparation and in situ protocol were
performed as previously in Guasti et al (2011).
When co-labeling was desired, after in situ, the sections were
incubated with primary antibodies (anti-GnRH, Immunostar; anti-
peripherin, Merck-Millipore; anti-isolectin B4, Sigma) diluted 1:1000
in PBS–Triton 0.1%, overnight at room temperature (RT) as used in
Cariboni et al (2011). After three washes with PBS–Triton 0.1%, the
slides were incubated for 2 h at RT with biotin-conjugated goat
secondary antibodies (Vector Laboratories), diluted 1:300 in PBS
and, after further washes, with the avidin–biotin complex (ABC
staining kit, Vector Laboratories). The sections were reacted with
40,60-diamino-2-phenylindole (DAPI, Vector Laboratories) and
mounted as above.
Images were acquired using a Leica DM5500B microscope (Leica,
Nussloch, Germany), equipped with a DCF295 camera (Leica) and
DCViewer software (Leica), and then processed with Abode Photo-
shop CS6 and Adobe Illustrator CS6.
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Migration experiments
Igsf10 silencing was achieved in NIH3T3 cells (sourced from ATCC)
using SureSilencing shRNA plasmids (QIAGEN) according to the
manufacturer’s instructions. Stable lines were obtained by puro-
mycin treatment (Life Technologies, 2 g/ml). Cells were checked for
mycoplasma contamination (MycoAlert Detection Kit, Lonza) on a
monthly basis and were contamination-free. The level of Igsf10
knockdown was assessed by RT–qPCR. RNA extraction (RNeasy
Mini kit, QIAGEN) and cDNA synthesis (M-MLV Reverse Transcrip-
tase, Promega) were performed according to the manufacturers’
instructions. RT–qPCR was performed in a 10-ll reaction mixture
containing 2 ll cDNA template, 5 ll 2 × SYBRGREEN I Master Mix
(KAPA Biosystems), 0.2 ll low ROX (KAPA Biosystems), 0.5 ll
primers (10 lM forward + reverse), and 2.3 ll nuclease-free H2O.
Gapdh was used as the endogenous housekeeping gene. The real-
time PCR was performed using an Mx3000 Thermocycler (Strata-
gene) using the following primers and conditions: mIgsf10: FOR,
50-CTGGGGAGTCCAATTGCTGT-30 and REV, 50-GCTGCCTTTGCTG
ACATC-30 (18 bp); Gapdh: FOR, 50-TGCACCACCAACTGCTTAG-30
and REV, 50-GGATGCAGGGATGATGTTC-30. Quantitative RT–qPCR
was set up in triplicate. After an initial denaturation step of 3 min at
95°C, PCR cycling was performed for 40 cycles of 95°C for 3 s, 55°C
for 20 s and 72°C for 1 s, followed by 1 cycle of 1 min at 95°C, 55°C
for 30 s and 95°C for 30 s. Silencing was achieved at 80% in
Igsf10-silenced NIH3T3 cells compared to cells expressing the
scrambled shRNA.
Micromass cultures were obtained with the immortalized GnRH-
expressing cell line GN11. Confluent monolayer cultures of GN11
were released by trypsin–EDTA and resuspended in growth medium.
Micromasses were obtained by pipetting 20 ll (4.0 × 105 cells) of
cell suspension onto the lid of a 10-cm petri dish and incubating for
48 h in a 5% CO2 incubator at 37°C. Micromasses were then placed
onto confluent scrambled and Igsf10-silenced NIH3T3 cells for
7 days. The cells were then fixed in 4% PFA, and GN11 migration
into NIH3T3 was assessed by staining with anti-GnRH antibodies, as
used in Cariboni et al (2011). Migration index was calculated by
assessing GnRH-stained cells using the ImageJ software (NIH).
Statistical significance was evaluated by ANOVA and Student’s
t-test. *P < 0.05 and **P < 0.01 were taken to be significant. Data
are presented as mean  standard error of mean and expressed as
percentage reduction of migration, taking untreated or scrambled
controls as 100%. Each experiment was performed using at least 12
micromasses/group and repeated three times.
Zebrafish investigations
Animals
A transgenic line, Tg(gnrh3:EGFP), was used to visualize GnRH3
neurons and their projections (Abraham et al, 2008). Wild-type and
transgenic zebrafish embryos were generated by natural mating.
Both AB and TL strains were used for the experiments. Embryos
were raised in fish water with methylene blue (0.3 p.p.m.) in petri
dishes at 28°C in a 12-h light/12-h dark cycle. Developmental stages
are expressed in hours post-fertilization (hpf) or days post-fertiliza-
tion (dpf). All embryos used in experiments were 5 dpf or younger.
Pigmentation was prevented by adding 0.2 mM phenylthiourea
(PTU) to the water at 24 hpf.
RT–PCR analysis
Total RNA was isolated from embryos and larvae at different stages
of embryogenesis using EZ RNA Total RNA Isolation kit (Biological
Industries, Beit Haemek, Israel). First-strand cDNA was synthesized
from 1 lg of total RNA by qScript cDNA kit (Quanta Biosciences,
Gaithersburg, MD, USA) according to the manufacturer’s protocol.
Primers for Igsf10: FOR, 50-TTGGCTACAGTCCCGATTTC-30 and REV,
50-AAATTTTGCTGGGACGAATG-30.
Morpholino-knockdown experiments
Morpholino-modified antisense oligonucleotides (MOs) (Gene Tools,
Philomath, OR, USA) were used to repress Igsf10mRNA to assess the
effect on the development of the GnRH3 system. A splice-site-MO
(Igsf10 Sp-MO 50-GCCTGTTGTAGGTTTTACCCCAGGT-30, 25 bp)
and an ATG-MO (Igsf10 ATG-MO 50-GGGAATCCGCTGCTGGGTCA-
CACAT-30, 25 bp) were designed. Quantities of 1.5pmol/embryo
(Igsf10 Sp-MO) or 1pmol/embryo (Igsf10 ATG-MO) were injected
into Tg(gnrh3:EGFP) embryos immediately after fertilization. In all
experiments, Igsf10 Sp-MO- or ATG-MO-injected embryos were
compared with embryos injected with the same amount of mispair
control (control Sp-MO 50-GCGTCTTGTACGTTTTACCCGACGT-30 or
control ATG-MO 50-GAGAATACGCTACTGGGTAACAAAT-30, both
25 bp) at the same developmental stage.
Two sets of experiments (biological replicates) were performed
and each experiment consisted of three groups: Sp-MO injected,
Ctrl-MO injected, and uninjected. No statistical method was used to
predetermine sample size. Rather, sample size was based on prelim-
inary data and observed effect sizes. Dead embryos or embryos that
were GFP negative at 48 hpf were excluded from the analysis.
Considering that MO injection can cause a death rate of 10–25% in
24-h-old embryos, we injected a large number of embryos in order
to establish a statistical significance. In the first experiment, the
mortality rate in the injected embryos, Sp-MO and Ctrl-MO, was
11% and in the second, it was 25%. The mortality rate in the unin-
jected embryos was 2.5 and 5.7%, respectively.
In the first experiment, 353 embryos were injected with Sp-MO,
260 embryos were injected with Ctrl-MO, and 244 embryos left
uninjected: 146 of 353, 108 of 260, and 100 of 244 embryos were
available and GFP positive for analysis at 48 hpf. In the second
experiment, 186 embryos were injected with Sp-MO, 157 embryos
were injected with Ctrl-MO, and 122 embryos left uninjected: 55 of
186, 52 of 157, and 56 of 122 embryos were available and GFP posi-
tive for analysis at 48 hpf. Sex of embryos was undetermined (sepa-
rate sexes can be detected only after 21–23 dpf).
Injected larvae were checked daily and the EGFP expression was
monitored under SZX12 fluorescent dissecting microscope (Olympus,
Tokyo, Japan) for 5 days. Quantification of the percentage of embryos
showing an abnormal GnRH3-neuron phenotype in Igsf10 splice-site-
MO (Sp-MO)-injected embryos compared to relative controls, injected
either with a mispair morpholino (control-MO) or uninjected, was
assessed by mean  standard error of mean, tested by one-way
ANOVA followed by Dunnett’s post hoc test.
Efficacy of Igsf10 Sp-MO was evaluated by RT–PCR. Injected and
uninjected embryos were sampled at 48 hpf and total RNA was
extracted (EZ RNA Total RNA Isolation kit, Biological Industries,
Beit Haemek, Israel); 1 lg of RNA was retro-transcribed using
qScript cDNA kit (Quanta Biosciences, Gaithersburg, MD, USA).
Specific primers corresponding to zebrafish Igsf10 exons 2 and 3
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(Igsf10-E2FOR 50-GCGGATTCCCGTCTGCTATGG-30 and Igsf10-
E3REV 50-TGCAGAGATGTGAGGCCACTGAAC-30) were used for
PCR amplification. PCR products were separated on an agarose gel,
extracted from gel using HiYield Gel/PCR DNA Fragments Extrac-
tion Kit (RBC Bioscience, New Taipei City, Taiwan), and sequenced.
Sequencing analysis demonstrated the insertion of 97 nucleotides
within the intron 2 of Igsf10 Sp-MO-injected embryos, which would
result in a frameshift and produce a dysfunctional Igsf10 protein in
these embryos (Appendix Fig S3).
Study approval
The study protocol was approved by the Ethics Committee for Pedi-
atrics, Adolescent Medicine and Psychiatry, Hospital District of
Helsinki and Uusimaa (and extended to encompass Kuopio,
Tampere, and Turku University Hospitals). UK ethical approval was
granted by the London-Chelsea NRES Committee. The study was
conducted in accordance with the guidelines of the Declaration of
Helsinki. All patients gave informed written consent prior to
inclusion in the study. All mouse experiments were conducted
under the Animal (Scientific Procedures) Act 1986, Project Licence
PPL 70/8269. The human embryonic and fetal material was
provided by the Joint MRC/Wellcome Trust Grant# 099175/Z/12/Z
Human Developmental Biology Resource (http://hdbr.org).
Statistics
For rare variant burden testing, Fisher’s exact test was used with a
multiple comparison adjustment applied post hoc using the Benja-
mini and Hochberg method (Benjamini et al, 2001). A threshold of
P < 0.025 was taken as significant. Fisher’s exact test was also used
for the analysis of HH cohort allele frequencies. The unpaired t-test
(two-tailed) was used for statistical analysis of auxological data
(Appendix Table S2).
For all experiments, data are expressed as the mean  SEM. To
determine the statistical significance, we used the unpaired t-test
(two-tailed) or, for multiple comparisons, a one-way ANOVA
followed by a Dunnett’s post hoc test. A P-value of less than 0.05
was considered statistically significant. Statistical analysis was
performed using GraphPad Prism4 (GraphPad Software).
Expanded View for this article is available online.
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